23. Patient A showed an improvement during the initial eight months after treatment with oxaiiplatin, Avastin, Xeloda and phenylbutyrate under the direction and control of Respondent. In late April 2011, imaging of the affected area of the brain tissue revealed that the affected area was shrinking. In late April 2011, Respondent recommended and directed that the treatment he changed by eliminating some of the medications being used for Patient A by the Clinic. In mid?May 201 l, imaging of the affected area of the brain tissue revealed that the affected area had resumed growing larger. Respondent failed to have and failed to document an adequate medical rationale for a change of therapy when Patient A?s related to cancer were improving after late January 2011 and prior to late April 2011. Respondent also failed to adequately supervise Violation (1) Section 157.001 of the Act, responsibility of a physician for medical acts delegated to persons acting under the physician?s supervision; (2) Section of the Act, based on Respondent?s violation of Board Rules 165.1, adequate maintenance of medical records; (3) Section of the Act, as further de?ned by Board Rules (4) Section of the Act, prescribes or administers a drug or treatment that is nontherapeutic in nature 0r nontherapeutic in a manner the drug or treatment is administered or prescribed; (5) Section of the Act, failure to supervise adequately the activities of those acting under the supervision of the physician; and (6) Section of the Act, failure to supervise adequately the activities of those acting under the supervision of the physician. . 24. Patient A?s initial improvement was not sustained after late April 2011, and Patient A?s medical condition deteriorated as the tumor growth and spread worsened. Respondent?s evaluation, diagnosis and treatment of Patient A ended at the end of October 2011. 25. The Clinic, under Respondent?s direction and control, billed Patient and Patient B?s healthcare insurance carrier for services and charges that were medically unnecessary and not adequately supported by documentation including the following: a. October 7 2010 Dr. Valladares/Of?ce Consultation $1,000.00 '2 Anti-cancer medication Page 10 of 202 23. Patient A showed an improvement during the initial eight months after treatment with oxaiiplatin, Avastin, Xeloda and phenylbutyrate under the direction and control of Respondent. In late April 2011, imaging of the affected area of the brain tissue revealed that the affected area was shrinking. In late April 2011, Respondent recommended and directed that the treatment he changed by eliminating some of the medications being used for Patient A by the Clinic. In mid?May 201 l, imaging of the affected area of the brain tissue revealed that the affected area had resumed growing larger. Respondent failed to have and failed to document an adequate medical rationale for a change of therapy when Patient A?s related to cancer were improving after late January 2011 and prior to late April 2011. Respondent also failed to adequately supervise Violation (1) Section 157.001 of the Act, responsibility of a physician for medical acts delegated to persons acting under the physician?s supervision; (2) Section of the Act, based on Respondent?s violation of Board Rules 165.1, adequate maintenance of medical records; (3) Section of the Act, as further de?ned by Board Rules (4) Section of the Act, prescribes or administers a drug or treatment that is nontherapeutic in nature 0r nontherapeutic in a manner the drug or treatment is administered or prescribed; (5) Section of the Act, failure to supervise adequately the activities of those acting under the supervision of the physician; and (6) Section of the Act, failure to supervise adequately the activities of those acting under the supervision of the physician. . 24. Patient A?s initial improvement was not sustained after late April 2011, and Patient A?s medical condition deteriorated as the tumor growth and spread worsened. Respondent?s evaluation, diagnosis and treatment of Patient A ended at the end of October 2011. 25. The Clinic, under Respondent?s direction and control, billed Patient and Patient B?s healthcare insurance carrier for services and charges that were medically unnecessary and not adequately supported by documentation including the following: a. October 7 2010 Dr. Valladares/Of?ce Consultation $1,000.00 '2 Anti-cancer medication Page 10 of 202 23. Patient A showed an improvement during the initial eight months after treatment with oxaiiplatin, Avastin, Xeloda and phenylbutyrate under the direction and control of Respondent. In late April 2011, imaging of the affected area of the brain tissue revealed that the affected area was shrinking. In late April 2011, Respondent recommended and directed that the treatment he changed by eliminating some of the medications being used for Patient A by the Clinic. In mid?May 201 l, imaging of the affected area of the brain tissue revealed that the affected area had resumed growing larger. Respondent failed to have and failed to document an adequate medical rationale for a change of therapy when Patient A?s related to cancer were improving after late January 2011 and prior to late April 2011. Respondent also failed to adequately supervise Violation (1) Section 157.001 of the Act, responsibility of a physician for medical acts delegated to persons acting under the physician?s supervision; (2) Section of the Act, based on Respondent?s violation of Board Rules 165.1, adequate maintenance of medical records; (3) Section of the Act, as further de?ned by Board Rules (4) Section of the Act, prescribes or administers a drug or treatment that is nontherapeutic in nature 0r nontherapeutic in a manner the drug or treatment is administered or prescribed; (5) Section of the Act, failure to supervise adequately the activities of those acting under the supervision of the physician; and (6) Section of the Act, failure to supervise adequately the activities of those acting under the supervision of the physician. . 24. Patient A?s initial improvement was not sustained after late April 2011, and Patient A?s medical condition deteriorated as the tumor growth and spread worsened. Respondent?s evaluation, diagnosis and treatment of Patient A ended at the end of October 2011. 25. The Clinic, under Respondent?s direction and control, billed Patient and Patient B?s healthcare insurance carrier for services and charges that were medically unnecessary and not adequately supported by documentation including the following: a. October 7 2010 Dr. Valladares/Of?ce Consultation $1,000.00 '2 Anti-cancer medication Page 10 of 202 Her-2/Neu Immuno?ourescent Study Molecule Isolate Nucleic VEG Vascular Endothelial Dr. Valladares/Prolonged Ser. Contact Genetic Examination EGFR Epidermal Growth Factor Dr. Valladares/Prolonged Ser. Contact Dr. Valladares/Prolonged Phys. In Of?c October 11 2010 Measure Blood Oxygen Level Sodium Phenylbutyrate 500 mg Sodium Phenylbutyrate 500 mg Dr. Visit October 12 2010 Sodium Phenyibutyrate 500 mg Measure Blood Oxygen Level Sodium Phenylbutyrate 500 mg Dr. Vatladares/Of?ce/Outpatient Visit Add Supplies - A 10 October 13 2010 Special Service Stat Dr. ValIadares/Of?ce/Outpatient Visit MG Magnesium Lipid Panel Sodium Phenylbutyrate 500 mg Molecular Diagnostics Genetic Examination LD Lactate Dehydrogenase Molecule Isolate Nucleic Molecule Nucleic Ampli, Each Sodium Phenylbutyrate 500 mg Nucleic Acid, High Resolute UA Urinalysis, Non?Auto Molecule Mutation Identify Measure Blood Oxygen Level Sodium Phenylbutyrate 500 mg Sodium Phenylbutyrate 500 mg October 14 2010 Measure Blood Oxygen Level Dr. Va1ladares/Of?ce/Outpatient Visit - October 15 2010 Therapeutic IV Push, Each A Sodium Phenylbutyrate 500 mg Page 1 1 of202 $350.00 $350.00 $142.00 $400.00 $350.00 $141.00 $400.0 $150.00 $250.00 $35.00 $60.00 $60.00 $125.00 $120.00 $35.00 $120.00 $125.00 $15.00 $125.00 $50.00 $50.00 $180.00 $90.00 $75.00 $25.00 $75.00 $80.00 $180.00 $140.00 $25.00 $140.00 $35.00 $240.00 $240.00 $35.00 $125.00 $100.00 $300.00 $1,080.00 A) Her-2/Neu Immuno?ourescent Study Molecule Isolate Nucleic VEG Vascular Endothelial Dr. Valladares/Prolonged Ser. Contact Genetic Examination EGFR Epidermal Growth Factor Dr. Valladares/Prolonged Ser. Contact Dr. Valladares/Prolonged Phys. In Of?c October 11 2010 Measure Blood Oxygen Level Sodium Phenylbutyrate 500 mg Sodium Phenylbutyrate 500 mg Dr. Visit October 12 2010 Sodium Phenyibutyrate 500 mg Measure Blood Oxygen Level Sodium Phenylbutyrate 500 mg Dr. Vatladares/Of?ce/Outpatient Visit Add Supplies - A 10 October 13 2010 Special Service Stat Dr. ValIadares/Of?ce/Outpatient Visit MG Magnesium Lipid Panel Sodium Phenylbutyrate 500 mg Molecular Diagnostics Genetic Examination LD Lactate Dehydrogenase Molecule Isolate Nucleic Molecule Nucleic Ampli, Each Sodium Phenylbutyrate 500 mg Nucleic Acid, High Resolute UA Urinalysis, Non?Auto Molecule Mutation Identify Measure Blood Oxygen Level Sodium Phenylbutyrate 500 mg Sodium Phenylbutyrate 500 mg October 14 2010 Measure Blood Oxygen Level Dr. Va1ladares/Of?ce/Outpatient Visit - October 15 2010 Therapeutic IV Push, Each A Sodium Phenylbutyrate 500 mg Page 1 1 of202 $350.00 $350.00 $142.00 $400.00 $350.00 $141.00 $400.0 $150.00 $250.00 $35.00 $60.00 $60.00 $125.00 $120.00 $35.00 $120.00 $125.00 $15.00 $125.00 $50.00 $50.00 $180.00 $90.00 $75.00 $25.00 $75.00 $80.00 $180.00 $140.00 $25.00 $140.00 $35.00 $240.00 $240.00 $35.00 $125.00 $100.00 $300.00 $1,080.00 A) Her-2/Neu Immuno?ourescent Study Molecule Isolate Nucleic VEG Vascular Endothelial Dr. Valladares/Prolonged Ser. Contact Genetic Examination EGFR Epidermal Growth Factor Dr. Valladares/Prolonged Ser. Contact Dr. Valladares/Prolonged Phys. In Of?c October 11 2010 Measure Blood Oxygen Level Sodium Phenylbutyrate 500 mg Sodium Phenylbutyrate 500 mg Dr. Visit October 12 2010 Sodium Phenyibutyrate 500 mg Measure Blood Oxygen Level Sodium Phenylbutyrate 500 mg Dr. Vatladares/Of?ce/Outpatient Visit Add Supplies - A 10 October 13 2010 Special Service Stat Dr. ValIadares/Of?ce/Outpatient Visit MG Magnesium Lipid Panel Sodium Phenylbutyrate 500 mg Molecular Diagnostics Genetic Examination LD Lactate Dehydrogenase Molecule Isolate Nucleic Molecule Nucleic Ampli, Each Sodium Phenylbutyrate 500 mg Nucleic Acid, High Resolute UA Urinalysis, Non?Auto Molecule Mutation Identify Measure Blood Oxygen Level Sodium Phenylbutyrate 500 mg Sodium Phenylbutyrate 500 mg October 14 2010 Measure Blood Oxygen Level Dr. Va1ladares/Of?ce/Outpatient Visit - October 15 2010 Therapeutic IV Push, Each A Sodium Phenylbutyrate 500 mg Page 1 1 of202 $350.00 $350.00 $142.00 $400.00 $350.00 $141.00 $400.0 $150.00 $250.00 $35.00 $60.00 $60.00 $125.00 $120.00 $35.00 $120.00 $125.00 $15.00 $125.00 $50.00 $50.00 $180.00 $90.00 $75.00 $25.00 $75.00 $80.00 $180.00 $140.00 $25.00 $140.00 $35.00 $240.00 $240.00 $35.00 $125.00 $100.00 $300.00 $1,080.00 A) . Measure Blood Oxygen Level Dr. Valladares/Of?ce/Outpatient Visit Intravenous push, Single Or Avastin 10 mg Xeloda Oral 500 mg October 16 2010 Sodium Phenylbutyrate 500 mg October 17 2010 Sodium Phenylbutyrate 500 mg October 18 2010 Lipid Panel Dr. Valladares/Of?ce/Outpatient Visit Sodium Phenylbutyrate 500 mg LD Lactate Dehydrogenasc Measure Blood Oxygen Level Special Service Stat October 19, 20.10 Sodium Phenyibutyrate 500 mg Measure Blood Oxygen Level Dr. Valladares/Of?ce/Outpatient Visit October 20 2010 Sodium Phenylbutyrate 500 mg October 21 2010 UA Urinalysis, Non-Auto WI Sodium Phenylbutyrate 500 mg Measure Blood Oxygen Level LD Lactate Dehydrogenase Lipid Panel . Dr. Va1ladares/Of?ce/Outpatient Visit October 22 2010 Lithium batteries, AA Intravenous Push, Single Or Avastin, 10 mg Sodium Phenylbutyrate 500 mg Measure Blood Oxygen Level Dr. Valladares/Of?ce/Outpatient Visit October 23 2010 Sodium Phenylbutyrate 500 mg October 24 2010 Sodium Phenylbutyrate 500 mg October 25 2010 Case Management Measure Blood Oxygen Level Dr. Va1ladares/Of?ce/Outpatient Visit Page 12 of 202 $35.00 $125.00 $125.00 $2,420.20 $1,887.73 $360.00 $360.00 $50.00 $125.00 $360.00 $25.00 $35.00 6 $15.00 $360.00 $35.00 $125.00 $360.00 $25.00 $3 60.00 - $35.00 (0 $25.00 $50.00 $125.00 $10.22 $125.00 $3,630.36 $360.00 $35.00 fl $125.00 $360.00 $360.00 $4,500.00 $35.00 1 25 .00 6 93/0/22. . Measure Blood Oxygen Level Dr. Valladares/Of?ce/Outpatient Visit Intravenous push, Single Or Avastin 10 mg Xeloda Oral 500 mg October 16 2010 Sodium Phenylbutyrate 500 mg October 17 2010 Sodium Phenylbutyrate 500 mg October 18 2010 Lipid Panel Dr. Valladares/Of?ce/Outpatient Visit Sodium Phenylbutyrate 500 mg LD Lactate Dehydrogenasc Measure Blood Oxygen Level Special Service Stat October 19, 20.10 Sodium Phenyibutyrate 500 mg Measure Blood Oxygen Level Dr. Valladares/Of?ce/Outpatient Visit October 20 2010 Sodium Phenylbutyrate 500 mg October 21 2010 UA Urinalysis, Non-Auto WI Sodium Phenylbutyrate 500 mg Measure Blood Oxygen Level LD Lactate Dehydrogenase Lipid Panel . Dr. Va1ladares/Of?ce/Outpatient Visit October 22 2010 Lithium batteries, AA Intravenous Push, Single Or Avastin, 10 mg Sodium Phenylbutyrate 500 mg Measure Blood Oxygen Level Dr. Valladares/Of?ce/Outpatient Visit October 23 2010 Sodium Phenylbutyrate 500 mg October 24 2010 Sodium Phenylbutyrate 500 mg October 25 2010 Case Management Measure Blood Oxygen Level Dr. Va1ladares/Of?ce/Outpatient Visit Page 12 of 202 $35.00 $125.00 $125.00 $2,420.20 $1,887.73 $360.00 $360.00 $50.00 $125.00 $360.00 $25.00 $35.00 6 $15.00 $360.00 $35.00 $125.00 $360.00 $25.00 $3 60.00 - $35.00 (0 $25.00 $50.00 $125.00 $10.22 $125.00 $3,630.36 $360.00 $35.00 fl $125.00 $360.00 $360.00 $4,500.00 $35.00 1 25 .00 6 93/0/22. . Measure Blood Oxygen Level Dr. Valladares/Of?ce/Outpatient Visit Intravenous push, Single Or Avastin 10 mg Xeloda Oral 500 mg October 16 2010 Sodium Phenylbutyrate 500 mg October 17 2010 Sodium Phenylbutyrate 500 mg October 18 2010 Lipid Panel Dr. Valladares/Of?ce/Outpatient Visit Sodium Phenylbutyrate 500 mg LD Lactate Dehydrogenasc Measure Blood Oxygen Level Special Service Stat October 19, 20.10 Sodium Phenyibutyrate 500 mg Measure Blood Oxygen Level Dr. Valladares/Of?ce/Outpatient Visit October 20 2010 Sodium Phenylbutyrate 500 mg October 21 2010 UA Urinalysis, Non-Auto WI Sodium Phenylbutyrate 500 mg Measure Blood Oxygen Level LD Lactate Dehydrogenase Lipid Panel . Dr. Va1ladares/Of?ce/Outpatient Visit October 22 2010 Lithium batteries, AA Intravenous Push, Single Or Avastin, 10 mg Sodium Phenylbutyrate 500 mg Measure Blood Oxygen Level Dr. Valladares/Of?ce/Outpatient Visit October 23 2010 Sodium Phenylbutyrate 500 mg October 24 2010 Sodium Phenylbutyrate 500 mg October 25 2010 Case Management Measure Blood Oxygen Level Dr. Va1ladares/Of?ce/Outpatient Visit Page 12 of 202 $35.00 $125.00 $125.00 $2,420.20 $1,887.73 $360.00 $360.00 $50.00 $125.00 $360.00 $25.00 $35.00 6 $15.00 $360.00 $35.00 $125.00 $360.00 $25.00 $3 60.00 - $35.00 (0 $25.00 $50.00 $125.00 $10.22 $125.00 $3,630.36 $360.00 $35.00 fl $125.00 $360.00 $360.00 $4,500.00 $35.00 1 25 .00 6 93/0/22. 'bb. CC. dd. ee. ff. Sodium Phenylbutyrate 500 mg November 8 2010 Add Supplies A10 November 18, 2010 Case Management December 6 2010 Case Management December 30 2010 Case Management anugy 24, 201 1 Add Supplies A10 February 8, 2011 Case Management March 18 2011 Case Management Match 24 2011 Case Management April 21, 2011 Case Management June 10 2011 Case Management August 3, 2011 Case Management August 29, 2011 Lipid Panel Dr. Va1ladares/Of?ee/Outpatient Visit Measure Blood Oxygen Level Auggst 30, 2011 A?nitor 10 mg Measure Blood Oxygen Level Dr. Valladares/Of?ce/Outpatient Visit September 1, 2011 Sodium Phenylbutyrate 500 mg Dr. Visit Chemo, IV Infusion 1 hr. Parenteral infusion pump portable Famotidine 20 mg Therapeutic IV Push, Each A Intravenous Push, Single Or Camptosar/Irinotecan 20 mg Measure Blood Oxygen Level Special Service Stat Lithium Batteries AA September 2, 201 1 Page 13 of 202 $360.00 $1,080.00 $4,500.00 $4,500.00 $4,500.00 $1,080.00 $2,250.00 $2,250.00 $2,250.00 $2,250.00 $2,250.00 $2,250.00 $50.00 $125.00 $35.00 $799.65 $35.00 $100.00 $3,600.00- $125.00 $198.00 $100.00 $100.00 $100.00 $125.00 $610.24 $35.00 $15.00 $10.22 'bb. CC. dd. ee. ff. Sodium Phenylbutyrate 500 mg November 8 2010 Add Supplies A10 November 18, 2010 Case Management December 6 2010 Case Management December 30 2010 Case Management anugy 24, 201 1 Add Supplies A10 February 8, 2011 Case Management March 18 2011 Case Management Match 24 2011 Case Management April 21, 2011 Case Management June 10 2011 Case Management August 3, 2011 Case Management August 29, 2011 Lipid Panel Dr. Va1ladares/Of?ee/Outpatient Visit Measure Blood Oxygen Level Auggst 30, 2011 A?nitor 10 mg Measure Blood Oxygen Level Dr. Valladares/Of?ce/Outpatient Visit September 1, 2011 Sodium Phenylbutyrate 500 mg Dr. Visit Chemo, IV Infusion 1 hr. Parenteral infusion pump portable Famotidine 20 mg Therapeutic IV Push, Each A Intravenous Push, Single Or Camptosar/Irinotecan 20 mg Measure Blood Oxygen Level Special Service Stat Lithium Batteries AA September 2, 201 1 Page 13 of 202 $360.00 $1,080.00 $4,500.00 $4,500.00 $4,500.00 $1,080.00 $2,250.00 $2,250.00 $2,250.00 $2,250.00 $2,250.00 $2,250.00 $50.00 $125.00 $35.00 $799.65 $35.00 $100.00 $3,600.00- $125.00 $198.00 $100.00 $100.00 $100.00 $125.00 $610.24 $35.00 $15.00 $10.22 'bb. CC. dd. ee. ff. Sodium Phenylbutyrate 500 mg November 8 2010 Add Supplies A10 November 18, 2010 Case Management December 6 2010 Case Management December 30 2010 Case Management anugy 24, 201 1 Add Supplies A10 February 8, 2011 Case Management March 18 2011 Case Management Match 24 2011 Case Management April 21, 2011 Case Management June 10 2011 Case Management August 3, 2011 Case Management August 29, 2011 Lipid Panel Dr. Va1ladares/Of?ee/Outpatient Visit Measure Blood Oxygen Level Auggst 30, 2011 A?nitor 10 mg Measure Blood Oxygen Level Dr. Valladares/Of?ce/Outpatient Visit September 1, 2011 Sodium Phenylbutyrate 500 mg Dr. Visit Chemo, IV Infusion 1 hr. Parenteral infusion pump portable Famotidine 20 mg Therapeutic IV Push, Each A Intravenous Push, Single Or Camptosar/Irinotecan 20 mg Measure Blood Oxygen Level Special Service Stat Lithium Batteries AA September 2, 201 1 Page 13 of 202 $360.00 $1,080.00 $4,500.00 $4,500.00 $4,500.00 $1,080.00 $2,250.00 $2,250.00 $2,250.00 $2,250.00 $2,250.00 $2,250.00 $50.00 $125.00 $35.00 $799.65 $35.00 $100.00 $3,600.00- $125.00 $198.00 $100.00 $100.00 $100.00 $125.00 $610.24 $35.00 $15.00 $10.22 Dr. Valladares/Of?ce/Outpatient Visit $125.00 Measure Blood Oxygen Level $35.00 gg. Segtembcr 6, 201 1 Lipid Panel $50.00 Dr. Valladares/Of?ce/Outpatient Visit $125.00 LD Lactate Dehydrogenase $25.00 Measure Blood Oxygen Level $35.00 Special Service Stat $15.00 MG Magnesium $50.00 1111. September 7, 2011 Votrient 200 mg $669.34 ii. September 8, 2011 A?nitor 100 mg $12,494.50 Votrient 200 mg $4,016.04 Measure. Blood Oxygen Level $35.00 Dr. Va1ladares/Of?ce/Outpatient Visit $125.00 jj. September 11, 2011 Sodium Phenylbutyrate 500 mg $3,600.00 kk. October 4 2011 Sodium Phenylbutyrate 500 mg $3,600.00 11. October 21 2011 IV Infusion Each Add Hour $150.00 Special Service Stat $15.00 Parenteral infuse pump portab $100.00 Lithium Batteries AA $10.22 Dr. Valladares/Of?ce/Outpatient Visit $125.00 Measure Blood Oxygen Level $35.00 IV Infusion Therapy $198.00 Patenteral. Nutrition 1 75 .00 mm. October 22 2011 Dr. Visit $75.00 IV Infusion Therapy $198.00 Patenteral Nutrition 1 75 .00 Measure Blood Oxygen Level $35.00 Ammonia Serum Panel $85.00 Lithium Batteries AA $10.22 26. Many of the impmper charges for evaluation, diagnosis and treatment of Patient A by the Clinic were done at the direction and control of Respondent, and were for medically unnecessary services. Many of the improper charges for evaluation, diagnosis and treatment of Patient A by the Clinic under the direction and control of Re5pondent Page 14 of 202 Dr. Valladares/Of?ce/Outpatient Visit $125.00 Measure Blood Oxygen Level $35.00 gg. Segtembcr 6, 201 1 Lipid Panel $50.00 Dr. Valladares/Of?ce/Outpatient Visit $125.00 LD Lactate Dehydrogenase $25.00 Measure Blood Oxygen Level $35.00 Special Service Stat $15.00 MG Magnesium $50.00 1111. September 7, 2011 Votrient 200 mg $669.34 ii. September 8, 2011 A?nitor 100 mg $12,494.50 Votrient 200 mg $4,016.04 Measure. Blood Oxygen Level $35.00 Dr. Va1ladares/Of?ce/Outpatient Visit $125.00 jj. September 11, 2011 Sodium Phenylbutyrate 500 mg $3,600.00 kk. October 4 2011 Sodium Phenylbutyrate 500 mg $3,600.00 11. October 21 2011 IV Infusion Each Add Hour $150.00 Special Service Stat $15.00 Parenteral infuse pump portab $100.00 Lithium Batteries AA $10.22 Dr. Valladares/Of?ce/Outpatient Visit $125.00 Measure Blood Oxygen Level $35.00 IV Infusion Therapy $198.00 Patenteral. Nutrition 1 75 .00 mm. October 22 2011 Dr. Visit $75.00 IV Infusion Therapy $198.00 Patenteral Nutrition 1 75 .00 Measure Blood Oxygen Level $35.00 Ammonia Serum Panel $85.00 Lithium Batteries AA $10.22 26. Many of the impmper charges for evaluation, diagnosis and treatment of Patient A by the Clinic were done at the direction and control of Respondent, and were for medically unnecessary services. Many of the improper charges for evaluation, diagnosis and treatment of Patient A by the Clinic under the direction and control of Re5pondent Page 14 of 202 Dr. Valladares/Of?ce/Outpatient Visit $125.00 Measure Blood Oxygen Level $35.00 gg. Segtembcr 6, 201 1 Lipid Panel $50.00 Dr. Valladares/Of?ce/Outpatient Visit $125.00 LD Lactate Dehydrogenase $25.00 Measure Blood Oxygen Level $35.00 Special Service Stat $15.00 MG Magnesium $50.00 1111. September 7, 2011 Votrient 200 mg $669.34 ii. September 8, 2011 A?nitor 100 mg $12,494.50 Votrient 200 mg $4,016.04 Measure. Blood Oxygen Level $35.00 Dr. Va1ladares/Of?ce/Outpatient Visit $125.00 jj. September 11, 2011 Sodium Phenylbutyrate 500 mg $3,600.00 kk. October 4 2011 Sodium Phenylbutyrate 500 mg $3,600.00 11. October 21 2011 IV Infusion Each Add Hour $150.00 Special Service Stat $15.00 Parenteral infuse pump portab $100.00 Lithium Batteries AA $10.22 Dr. Valladares/Of?ce/Outpatient Visit $125.00 Measure Blood Oxygen Level $35.00 IV Infusion Therapy $198.00 Patenteral. Nutrition 1 75 .00 mm. October 22 2011 Dr. Visit $75.00 IV Infusion Therapy $198.00 Patenteral Nutrition 1 75 .00 Measure Blood Oxygen Level $35.00 Ammonia Serum Panel $85.00 Lithium Batteries AA $10.22 26. Many of the impmper charges for evaluation, diagnosis and treatment of Patient A by the Clinic were done at the direction and control of Respondent, and were for medically unnecessary services. Many of the improper charges for evaluation, diagnosis and treatment of Patient A by the Clinic under the direction and control of Re5pondent Page 14 of 202